Biotech Archives - Page 80 of 795

2 minute read

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

April 5, 12:57 PM

Explore TARA-002's data in NMIBC treatment. Discover findings from three trials, including response rates, adverse events, and future plans. Stay updated on Protara Therapeutics' advancements in cancer therapy and FDA alignment for Choline Chloride.

TARA

2 minute read

New Hope for Aggressive Lung Cancer: AstraZeneca’s Imfinzi Shows Promising Results in Phase 3 Trial

By Vandana Singh

April 5, 10:19 AM

High-level results of AstraZeneca's ADRIATIC Phase 3 trial on Imfinzi monotherapy & Imfinzi plus Imjudo for limited-stage small cell lung cancer. Statistically significant OS & PFS improvement shown vs. placebo.

AZN

1 minute read

What’s Going On With Candel Therapeutics Stock On Friday?

By Vandana Singh

April 5, 9:22 AM

Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for non-metastatic prostate cancer. Exciting developments continue with updated data from ongoing phase 1b trial of CAN-3110 for recurrent high-grade glioma

CADL

3 minute read

U.S. FDA Approves Bristol Myers Squibb And 2seventy bio’s Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 Ka…

By Benzinga Newsdesk

April 5, 9:07 AM

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profileExpanded approval

BMY

2 minute read

Lipella Pharmaceuticals To Publish Abstract Detailing Compelling Preclinical Support For New Product Candidate At ASCO 2024

By Benzinga Newsdesk

April 5, 8:00 AM

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has

LIPO

2 minute read

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism Of Action Of SNS-101 Selectively Targeting The Active Form Of VISTA Within The Tumor Microenvironment

By Benzinga Newsdesk

April 4, 4:10 PM

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a

SNSE

3 minute read

Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus

By Benzinga Newsdesk

April 4, 4:01 PM

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy

CRBU

1 minute read

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

By Vandana Singh

April 4, 2:32 PM

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

ABUS

1 minute read

Why Is Novartis Stock Trading Higher On Thursday?

By Vandana Singh

April 4, 2:09 PM

Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile remains stable.

NVS

1 minute read

FDA
News

Nexalin Technology Awarded Key Patent Related To Gen-3 HALO Clarity

By Benzinga Newsdesk

April 4, 1:12 PM

Mark White, CEO of Nexalin Technology, stated, "This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology. These patents extend through 2040

NXL